141 related articles for article (PubMed ID: 16733240)
1. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.
Sarafidis PA; Lasaridis AN
Am J Hypertens; 2006 Jun; 19(6):646-53. PubMed ID: 16733240
[TBL] [Abstract][Full Text] [Related]
2. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
4. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
6. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
Dobrian AD
Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
[TBL] [Abstract][Full Text] [Related]
7. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
10. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
[TBL] [Abstract][Full Text] [Related]
13. PPAR agonists and the metabolic syndrome.
Staels B
Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
[TBL] [Abstract][Full Text] [Related]
14. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
Feinstein DL; Spagnolo A; Akar C; Weinberg G; Murphy P; Gavrilyuk V; Dello Russo C
Biochem Pharmacol; 2005 Jul; 70(2):177-88. PubMed ID: 15925327
[TBL] [Abstract][Full Text] [Related]
15. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
16. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS
Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
19. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
20. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
